An interventional study of Folic Acid 1 MG and Vitamin B6 25 MG in Parkinson&Amp;#39;s Disease, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-01-13.
Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Parkinson Disease by Oregon Health and Science University — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · Oregon Health and Science University.
Among the 36 studies in Parkinson Disease by Oregon Health and Science University, this one is the 2nd largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2024, is one of 17 with no phase, and was the 35th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →4 of the 36 studies in Parkinson Disease by Oregon Health and Science University are open now, in 2 countries. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States, Brazil
Ages 50–80
Oregon Health and Science University · Sites in United States
Ages 45–85
Oregon Health and Science University · Sites in United States
Ages 55–85
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 22 across the 28 interventional studies, 17 across the 8 observational. Of the 26 that completed or were terminated, 10 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Oregon Health and Science University is the lead sponsor of 697 studies on the registry; 129 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 39 (74%) have results posted.
3 of the studies in Parkinson Disease by Oregon Health and Science University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06815302Oregon Health and Science UniversityTURN-IT FOG: Improving Turning and Freezing of Gait in People With PD | 2026-12-31 |
| NCT05680597Oregon Health and Science UniversityBalance Tele-Rehab in Parkinson's Disease | 2027-06 |
| NCT05818189Oregon Health and Science UniversityCortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cueing | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Parkinson Disease by Oregon Health and Science University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily doses of 1mg folic acid, 25mg vitamin B6, and 1,000 ug vitamin B12.
Dietary Supplement: Folic Acid 1 MG · Dietary Supplement: Vitamin B6 25 MG · Dietary Supplement: Vitamin B12
No vitamin intervention.
Folic Acid 1mg per day
Drug pages: Vitamin B 6Studies of Vitamin B 6Vitamin B 6 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PyridoxineStudies of PyridoxinePyridoxine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Vitamin B6, 25mg per day
Vitamin B12, 1,000 ug per day
Hyperhomocysteinemia and B vitamin deficiency
Plasma vitamin B12 in subjects with vs without hyperhomocysteinemia
Time frame: baseline measurement
Hyperhomocysteinemia and B vitamin deficiency
Plasma folic acid in subjects with vs without hyperhomocysteinemia
Time frame: baseline measurement
Hyperhomocysteinemia and B vitamin deficiency
Plasma pyridoxine in subjects with vs without hyperhomocysteinemia
Time frame: baseline measurement
Hyperhomocysteinemia and cognitive assessments
Change in total Braincheck score in subjects with vs without hyperhomocysteinemia
Time frame: From enrollment to the end of treatment at 3 months
Hyperhomocysteinemia and measurement of neurofilament light in plasma
Change in plasma neurofilament level in subjects with vs without hyperhomocysteinemia
Time frame: From enrollment to the end of treatment at 3 months
Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 21 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Folic Acid · Vitamin B 6 · Pyridoxine · Vitamin B 12
Oregon Health and Science University →